6533b7defe1ef96bd1276705

RESEARCH PRODUCT

Glucose insulin potassium infusion improves systolic function in patients with chronic ischemic cardiomyopathy

subject

description

Objective: We assessed the effects of glucose–insulin–potassium (GIK) by echocardiography in stable patients with ischemic dysfunction. Methods: Twelve male patients with stable coronary disease (SCD) and ejection fraction (EF) <45% were studied for systolic function. GIK (glucose 30%, 300 insulin units and KCl 6 g/l) was infused at 1 ml/kg per h over 20 min. Hemodynamic and echocardiographic measurements were recorded at rest (T0), at the end (20 min) of GIK infusion (T + 20), 20 and 40 min after the end of the infusion (T + 40 and T + 60). Results: At T + 20, a significant decrease in WMSI (wall motion score index) was observed compared with T0 (2.16±0.14 vs. 2.30±0.16: P<0.05). An increase in EF was reported at T + 40 and T + 60 compared with T0 (44.1±7.8% and 53.3±11.6% vs. 35.6±4.5%, respectively: P<0.01). A decrease in WMSI was observed at T + 40 and T + 60 compared with rest (2.02±0.17 and 1.93±0.11 vs. 2.30±0.16, respectively: P<0.01). Conclusion: Our present work suggests that GIK infusion improves systolic function in patients with SCD and ejection fraction <45%. Further studies are needed to determine if short-term GIK infusion could be useful for therapeutic or diagnostic strategies in these patients.